BR112012004167A2 - métodos para a prevenção e o tratamento de isquemia cerebral - Google Patents

métodos para a prevenção e o tratamento de isquemia cerebral

Info

Publication number
BR112012004167A2
BR112012004167A2 BR112012004167A BR112012004167A BR112012004167A2 BR 112012004167 A2 BR112012004167 A2 BR 112012004167A2 BR 112012004167 A BR112012004167 A BR 112012004167A BR 112012004167 A BR112012004167 A BR 112012004167A BR 112012004167 A2 BR112012004167 A2 BR 112012004167A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
methods
cerebral ischemia
ischemia
Prior art date
Application number
BR112012004167A
Other languages
English (en)
Portuguese (pt)
Inventor
Guy M Miller
Viktoria Kheifets
Original Assignee
Edison Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edison Pharmaceuticals Inc filed Critical Edison Pharmaceuticals Inc
Publication of BR112012004167A2 publication Critical patent/BR112012004167A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012004167A 2009-08-26 2010-08-24 métodos para a prevenção e o tratamento de isquemia cerebral BR112012004167A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27526909P 2009-08-26 2009-08-26
PCT/US2010/046503 WO2011025785A1 (en) 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia

Publications (1)

Publication Number Publication Date
BR112012004167A2 true BR112012004167A2 (pt) 2016-03-29

Family

ID=42983642

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004167A BR112012004167A2 (pt) 2009-08-26 2010-08-24 métodos para a prevenção e o tratamento de isquemia cerebral

Country Status (17)

Country Link
US (3) US20110207828A1 (https=)
EP (1) EP2470168B1 (https=)
JP (2) JP5785546B2 (https=)
CN (1) CN102647981B (https=)
AU (1) AU2010286704B2 (https=)
BR (1) BR112012004167A2 (https=)
CA (1) CA2772294C (https=)
DK (1) DK2470168T3 (https=)
EA (1) EA028677B1 (https=)
ES (1) ES2663709T3 (https=)
HU (1) HUE037592T2 (https=)
MX (1) MX337990B (https=)
NO (1) NO2470168T3 (https=)
PL (1) PL2470168T3 (https=)
PT (1) PT2470168T (https=)
SI (1) SI2470168T1 (https=)
WO (1) WO2011025785A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
EP2471530B1 (en) * 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2009061744A2 (en) 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (ru) * 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2741767C (en) 2008-10-28 2017-09-12 Ptc Therapeutics, Inc. Process for the production of alpha-tocotrienol and derivatives
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
US20110172312A1 (en) * 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
CA2797581A1 (en) * 2010-04-27 2011-11-03 Edison Pharmaceuticals, Inc. Formulations of quinones for the treatment of ophthalmic diseases
WO2012119065A2 (en) 2011-03-03 2012-09-07 Seachaid Pharmaceuticals, Inc. Antifungal agents and uses thereof
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
GB201117808D0 (en) * 2011-10-14 2011-11-30 Siemens Medical Solutions SUV correction following dose infiltration
SI3677252T1 (sl) * 2012-03-19 2024-02-29 Cidara Therapeutics, Inc. Sheme odmerjanja za spojine iz razreda ehinokandinov
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
CN112451518B (zh) * 2012-11-13 2025-02-21 因维克特斯生物技术有限公司 生育三烯酚的经粘膜递送
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
RU2578451C1 (ru) * 2014-12-09 2016-03-27 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации Способ повышения устойчивости головного мозга к ишемии во время реконструктивных операций на брахиоцефальных артериях
AU2015364640B2 (en) 2014-12-16 2020-08-13 Ptc Therapeutics, Inc. Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
EP3390377B1 (en) 2015-12-16 2026-03-25 PTC Therapeutics, Inc. Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
MA43825A (fr) 2016-03-16 2021-04-07 Cidara Therapeutics Inc Schémas posologiques pour le traitement d'infections fongiques
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
JP7779651B2 (ja) 2017-07-12 2025-12-03 ナップ ファーマシューティカル グループ リミテッド 真菌感染症の処置のための組成物及び方法
BR112021000018A2 (pt) * 2018-07-03 2021-07-06 Venturis Therapeutics Inc composições e métodos para tratamento de acidente vascular cerebral
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
KR20210076956A (ko) 2018-10-17 2021-06-24 피티씨 테라퓨틱스, 인크. α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온
CN114746430B (zh) 2019-10-04 2026-01-30 康德生物医疗有限公司 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物
CN114729018A (zh) * 2019-10-17 2022-07-08 宾州研究基金会 再生功能神经元以治疗出血性中风
US12037350B2 (en) 2020-04-03 2024-07-16 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
JP2023553728A (ja) * 2020-12-22 2023-12-25 コーニンクレッカ フィリップス エヌ ヴェ 血管狭窄の位置特定
CN113066113B (zh) * 2021-04-27 2022-01-11 河北医科大学第二医院 自发性高血压大鼠脑模板和地图集的构建方法及设备
PE20240893A1 (es) 2021-07-08 2024-04-24 Ptc Therapeutics Inc Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938203B2 (ja) * 1976-04-26 1984-09-14 エーザイ株式会社 補酵素ｑを主成分とする脳循環障害治療剤
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US6232060B1 (en) * 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
WO1999025336A1 (en) 1997-11-17 1999-05-27 Lipogenics, Inc. Methods for preventing restenosis using tocotrienols
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6346544B2 (en) * 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
DE10034233A1 (de) * 2000-07-14 2002-01-24 Basf Ag Tocotrienolchinon-Cyclisierungsprodukte
WO2002047680A2 (en) * 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6608196B2 (en) * 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
WO2003015494A2 (en) * 2001-08-21 2003-02-27 Galileo Pharmaceuticals, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
AU2002352726A1 (en) * 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US20040152764A1 (en) * 2001-12-14 2004-08-05 Miller Guy M. Compositions and methods for the prevention and treatment of cerebral ischemia
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
JP4599292B2 (ja) * 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
EP2471530B1 (en) * 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2622523C (en) * 2005-09-15 2014-02-18 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) * 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2008086025A2 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
WO2009061744A2 (en) * 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2009088572A2 (en) * 2008-01-07 2009-07-16 Centocor, Inc. Method of treating erythropoietin hyporesponsive anemias
EA023618B1 (ru) * 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
WO2009111576A2 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2262519A4 (en) * 2008-03-05 2011-03-23 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCING DISORDERS WITH REDOXACTIVE THERAPEUTICS
CA2723621A1 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
WO2009143268A2 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
WO2010005989A1 (en) * 2008-07-09 2010-01-14 Edison Pharmaceuticals, Inc. Dermatological compositions with anti-aging and skin even-toning properties
US20100029784A1 (en) * 2008-07-30 2010-02-04 Hinman Andrew W Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
EP2344142B1 (en) * 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) * 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2741767C (en) * 2008-10-28 2017-09-12 Ptc Therapeutics, Inc. Process for the production of alpha-tocotrienol and derivatives
JP2012525397A (ja) * 2009-04-28 2012-10-22 エジソン ファーマシューティカルズ， インコーポレイテッド 眼科疾患を治療するためのトコトリエノールキノンの製剤
EP2424360A4 (en) * 2009-04-28 2012-10-03 Ampere Life Sciences Inc TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
PL2424495T3 (pl) * 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
EP2609921A1 (en) * 2009-06-25 2013-07-03 Ampere Life Sciences, Inc. Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
US20110172312A1 (en) * 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
AU2011238525A1 (en) * 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
CA2797581A1 (en) * 2010-04-27 2011-11-03 Edison Pharmaceuticals, Inc. Formulations of quinones for the treatment of ophthalmic diseases
US20120101169A1 (en) * 2010-07-14 2012-04-26 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control

Also Published As

Publication number Publication date
EP2470168B1 (en) 2018-01-31
JP5785546B2 (ja) 2015-09-30
SI2470168T1 (en) 2018-05-31
JP2013503168A (ja) 2013-01-31
AU2010286704A1 (en) 2012-03-22
PT2470168T (pt) 2018-03-28
AU2010286704B2 (en) 2016-10-20
US20170007553A1 (en) 2017-01-12
CA2772294A1 (en) 2011-03-03
DK2470168T3 (en) 2018-05-07
CN102647981A (zh) 2012-08-22
NO2470168T3 (https=) 2018-06-30
EA028677B1 (ru) 2017-12-29
MX2012002374A (es) 2012-04-10
US20180344667A1 (en) 2018-12-06
US20110207828A1 (en) 2011-08-25
CA2772294C (en) 2018-08-21
MX337990B (es) 2016-03-30
JP2015091899A (ja) 2015-05-14
EA201200355A1 (ru) 2012-07-30
PL2470168T3 (pl) 2018-06-29
WO2011025785A1 (en) 2011-03-03
CN102647981B (zh) 2016-09-28
EP2470168A1 (en) 2012-07-04
ES2663709T3 (es) 2018-04-16
HUE037592T2 (hu) 2018-09-28

Similar Documents

Publication Publication Date Title
BR112012004167A2 (pt) métodos para a prevenção e o tratamento de isquemia cerebral
BR112013018754A2 (pt) combinação de componentes para a prevenção e tratamento de fragilidade
SI2448637T2 (sl) Uporaba enega ali kombinacije fito-kanabinoidov pri zdravljenju epilepsije
PT2285387E (pt) Nutrição para a prevenção de infeções
BR112012002269A2 (pt) implemento para tratar superfície
BR112013016535A2 (pt) extratos vegetais para o tratamento e prevenção de infecções
PT2523661T (pt) Inibidores de nkcc para o tratamento de autismo
BRPI0918527A2 (pt) compostos para o tratamento de disturbios do cns
BR112012011730A2 (pt) tratamentos para distúrbios gastrointestinais
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
BR112012004395A2 (pt) liberação de sdf-1 para tratamento do tecido isquêmico
BRPI1015274A2 (pt) instalação para o tratamento de superfície de peças
SMT201900015T1 (it) Medicamento per uso topico a base di acido ialuronico solfatato per il trattamento dei coaguli di fibrina e dei trombi
HUE040085T2 (hu) PDE7 inhibitorok alkalmazása mozgási rendellenességek kezelésére
BRPI1011438A2 (pt) retentor de travamento para prendedores roscados
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI1010516A2 (pt) Métodos de tratamento de edema relacionados à isquemia-reperfusão
BR112013031702A2 (pt) 1-piperazino-3-fenil indanos deuterados para o tratamento de esquizofrenia
BR112013012094A2 (pt) método para a purifação de misturas
BRPI1011337A2 (pt) dispositivo de segurança para fixador rápido
BRPI1009435A2 (pt) tratamento para câncer no pâncreas
BRPI1015535A2 (pt) coquilha para lingotamento contínuo
PT2841075T (pt) Agentes e métodos para tratamento e prevenção de queratose seborreica
BR112012007256A2 (pt) dispositivo para tratamento de água
BR112013018453A2 (pt) métodos e composições para a prevenção e tratamento de osteoartrite

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOELECTRON TECHNOLOGY CORPORATION (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]